Press release
Health Care
September 15, 2021

Evonik’s AvailOm® omega-3 powder for dietary supplements now available in Brazil

  • Highest-load omega-3 powder and formulation know-how now accessible to Brazilian companies and consumers
  • Strong market demand for dietary supplements in Latin America
  • Omega-3 fish oil-based grades: AvailOm® 50 High EPA and AvailOm® 50 High DHA


Sao Paulo, Brazil. Two fish oil-based grades of Evonik’s high-load omega-3 powder platform AvailOm® are accessible in Brazil for the first time. Evonik has received approval from the Brazilian health authority ANVISA for the distribution of AvailOm® 50 High EPA and AvailOm® 50 High DHA. Nutraceutical companies and consumers in Brazil can now benefit from a complete system solution that encompasses Evonik’s formulation know-how and the AvailOm® platform.

“We are proud to now bring both this superior ingredient and our global formulation capabilities to Brazilian consumers, and we look forward to expanding this offering in Brazil and beyond in Latin America,” said Gilles Razzauti, director of Advanced Food Ingredients at Evonik’s Health Care business. Brazil has the largest market for nutraceuticals in Latin America and the demand for omega-3 dietary supplements continues to grow strongly.

Omega-3 is a critical ingredient in formulations for dietary supplements tailored to healthy agers, pregnant women, and other consumer groups. AvailOm® is produced using Evonik’s proprietary process that combines free fatty acids with the essential amino acid L-lysine. The complex formed is easy to process into a wide range of final formulations with no fishy aftertaste.

AvailOm® has a bioavailability more than five times higher than traditional omega-3 fish oil soft-gel capsules. The powders are directly compressible into tablets and allow nutraceutical companies a wide range of opportunities to develop differentiated combination products with other active ingredients such as botanicals, vitamins, proteins and minerals for enhanced performance and synergistic benefits.

AvailOm® 50 High DHA is a supplement solution ideal for use during pregnancy and early motherhood and to support eye function or brain health in later stages of life. AvailOm® 50 High EPA promotes heart health, joint health and reduces inflammation. All AvailOm® grades are produced from certified sustainable sources to protect marine ecosystems.

The AvailOm® platform is part of a nutraceuticals portfolio of advanced health ingredients, coatings, formulation services and finished dosage forms offered by Evonik’s Health Care business. As part of the life sciences division, Nutrition & Care, Evonik Health Care has centred its business on improving health and quality of life. The division is characterized by high growth prospects and above average margin potential.


Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.